Review Article

Adjuvant Treatment of Melanoma

Table 14

Systematic data review.

SP (%; 95% credible interval)
Month 6Month 12Month 24Month 36Month 48Median OS

DTIC60.9 (58.5–63.2)36.3 (33.6–39.2)12.1 (9.3–15.4)3.7 (01.09–06.03)1.0 (0.2–2.7)11.0 (10–12.2)
DTIC + IFN60.9 (53.9–67.2)36.9 (29.6–44.5)13.5 (7.3–21.7)4.9 (1–12.7)NA11.5 (9.2–15.4)
DTIC non IFN59.7 (50.3–67)35.6 (26.4–43.9)12.7 (6.8–20)4.6 (1.1–11)1.7 (0.1–7)11.2 (8.7–14.5)
DTIC + Oblimersen64.2 (58.4–70.5)41.2 (34.9–48)16.8 (11.3–23.2)NANA12.9 (10.8–16)
TMZ64.8 (60.1–69.5)39.5 (34.2–44.9)11.9 (7.3–17.5)2.5 (0.5–6.8)NA11.3 (9.8–13.2)
TMZ + IFN67.6 (59.4–75.2)43.6 (34.4–53.3)15.2 (8–24.5)4.0 (0.6–11.9)NA12.5 (10.1–16.1)
TMZ non IFN69.6 (61.1–78.4)45.5 (34.9–56.8)15.0 (6.4–27)NANA12.6 (9.9–17.1)
DTIC + IPI70.2 (63.8–75.3)48.4 (40.7–55.1)21.3 (14.8–28.7)8.5 (3.6–15.6)3.1 (0.5–9.2)14.7 (12.2–18.1)